NO20053302L - Imidazolderivater med affinitet for alfa 2-reseptoraktivitet. - Google Patents
Imidazolderivater med affinitet for alfa 2-reseptoraktivitet.Info
- Publication number
- NO20053302L NO20053302L NO20053302A NO20053302A NO20053302L NO 20053302 L NO20053302 L NO 20053302L NO 20053302 A NO20053302 A NO 20053302A NO 20053302 A NO20053302 A NO 20053302A NO 20053302 L NO20053302 L NO 20053302L
- Authority
- NO
- Norway
- Prior art keywords
- unsubstituted
- substituted
- affinity
- alpha
- prodrug forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20022159A FI20022159A0 (fi) | 2002-12-05 | 2002-12-05 | Uusia farmaseuttisia yhdisteitä |
PCT/FI2003/000933 WO2004050635A2 (en) | 2002-12-05 | 2003-12-05 | Imidazol derivatives having affinity for alpha 2 receptors activity |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20053302L true NO20053302L (no) | 2005-07-05 |
NO20053302D0 NO20053302D0 (no) | 2005-07-05 |
NO330392B1 NO330392B1 (no) | 2011-04-04 |
Family
ID=8565048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20053302A NO330392B1 (no) | 2002-12-05 | 2005-07-05 | Imidazolderivater med affinitet for alfa 2-reseptoraktivitet og anvendelser derav, samt farmasoytisk preparat omfattende imidazolderivat |
Country Status (27)
Country | Link |
---|---|
US (1) | US7759496B2 (no) |
EP (1) | EP1572198B1 (no) |
JP (1) | JP4667042B2 (no) |
KR (1) | KR20050114603A (no) |
CN (1) | CN100560070C (no) |
AT (1) | ATE323484T1 (no) |
BR (1) | BR0317024A (no) |
CA (1) | CA2508335C (no) |
CY (1) | CY1105699T1 (no) |
DE (1) | DE60304741T2 (no) |
DK (1) | DK1572198T3 (no) |
EA (1) | EA008251B1 (no) |
ES (1) | ES2262031T3 (no) |
FI (1) | FI20022159A0 (no) |
HR (1) | HRP20050617B1 (no) |
IL (1) | IL168882A (no) |
IS (1) | IS2282B (no) |
ME (1) | ME00521B (no) |
MX (1) | MXPA05005963A (no) |
NO (1) | NO330392B1 (no) |
NZ (1) | NZ540466A (no) |
PL (1) | PL216530B1 (no) |
PT (1) | PT1572198E (no) |
RS (1) | RS52571B (no) |
SI (1) | SI1572198T1 (no) |
WO (1) | WO2004050635A2 (no) |
ZA (1) | ZA200504533B (no) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7700592B2 (en) | 2005-08-25 | 2010-04-20 | Schering Corporation | α2C adrenoreceptor agonists |
US8003624B2 (en) | 2005-08-25 | 2011-08-23 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
CN101374830A (zh) | 2005-08-25 | 2009-02-25 | 先灵公司 | α2C肾上腺素受体激动剂 |
EP2356106A1 (en) | 2008-10-07 | 2011-08-17 | Schering Corporation | Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4673679A (en) * | 1986-05-14 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration |
GB9425211D0 (en) * | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
GB9520150D0 (en) | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
JPH10195056A (ja) * | 1996-11-12 | 1998-07-28 | Takeda Chem Ind Ltd | 縮合ベンゼン誘導体、その製造法および剤 |
EP1117399B1 (en) * | 1998-09-28 | 2005-02-09 | Orion Corporation | Use of 3-(1h-imidazol-4-ylmethyl)-indan-5-ol in the manufacture of a medicament for intraspinal, intrathecal or epidural administration |
ATE312606T1 (de) | 1999-10-29 | 2005-12-15 | Orion Corp | Verwendung eines imidazolderivats zur behandlung oder verhütung von hypotension und schock |
US6388090B2 (en) | 2000-01-14 | 2002-05-14 | Orion Corporation | Imidazole derivatives |
FI20000073A0 (fi) * | 2000-01-14 | 2000-01-14 | Orion Yhtymae Oy | Uusia imidatsolijohdannaisia |
US7091232B2 (en) | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7439268B2 (en) * | 2003-07-18 | 2008-10-21 | Idexx Laboratories | Compositions containing prodrugs of florfenicol and methods of use |
-
2002
- 2002-12-05 FI FI20022159A patent/FI20022159A0/fi unknown
-
2003
- 2003-12-05 ME MEP-2008-864A patent/ME00521B/me unknown
- 2003-12-05 US US10/537,622 patent/US7759496B2/en active Active
- 2003-12-05 KR KR1020057009983A patent/KR20050114603A/ko active Search and Examination
- 2003-12-05 MX MXPA05005963A patent/MXPA05005963A/es active IP Right Grant
- 2003-12-05 CA CA2508335A patent/CA2508335C/en not_active Expired - Lifetime
- 2003-12-05 AT AT03812203T patent/ATE323484T1/de active
- 2003-12-05 BR BR0317024-1A patent/BR0317024A/pt unknown
- 2003-12-05 RS YU20050428A patent/RS52571B/en unknown
- 2003-12-05 SI SI200330300T patent/SI1572198T1/sl unknown
- 2003-12-05 EA EA200500922A patent/EA008251B1/ru not_active IP Right Cessation
- 2003-12-05 PT PT03812203T patent/PT1572198E/pt unknown
- 2003-12-05 EP EP03812203A patent/EP1572198B1/en not_active Expired - Lifetime
- 2003-12-05 NZ NZ540466A patent/NZ540466A/en not_active IP Right Cessation
- 2003-12-05 ES ES03812203T patent/ES2262031T3/es not_active Expired - Lifetime
- 2003-12-05 DK DK03812203T patent/DK1572198T3/da active
- 2003-12-05 DE DE60304741T patent/DE60304741T2/de not_active Expired - Lifetime
- 2003-12-05 PL PL377530A patent/PL216530B1/pl unknown
- 2003-12-05 JP JP2004556387A patent/JP4667042B2/ja not_active Expired - Fee Related
- 2003-12-05 CN CNB2003801051320A patent/CN100560070C/zh not_active Expired - Lifetime
- 2003-12-05 WO PCT/FI2003/000933 patent/WO2004050635A2/en active IP Right Grant
-
2005
- 2005-05-30 IL IL168882A patent/IL168882A/en not_active IP Right Cessation
- 2005-06-02 ZA ZA200504533A patent/ZA200504533B/en unknown
- 2005-06-23 IS IS7911A patent/IS2282B/is unknown
- 2005-07-04 HR HRP20050617AA patent/HRP20050617B1/hr not_active IP Right Cessation
- 2005-07-05 NO NO20053302A patent/NO330392B1/no not_active IP Right Cessation
-
2006
- 2006-07-03 CY CY20061100913T patent/CY1105699T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE556058T1 (de) | 1-(2h)-isochinolonderivat | |
DK1261602T3 (da) | Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer | |
EA200601235A1 (ru) | Производные тиазола | |
DK1178967T3 (da) | Quinolinderivater som inhibitorer af MEK-enzymer | |
UA83243C2 (ru) | Соединения, которые ингибируют натриезависимый переносчик глюкозы | |
NO20062269L (no) | Pyridin-karboksylsyrederivater som glucokinasemodulatorer | |
RS49850B (sr) | Derivati 1,4-benzotiazepin-1,1-dioksida supstituisani radikalima šećera, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena | |
IL161559A0 (en) | Dibenzylamine derivatives and pharmaceutical compositions containing the same | |
DK0976748T3 (da) | Pyrrolidinderivater med phospholispase A2-hæmmende aktivitet | |
AR025386A1 (es) | Moduladores de los receptores activados del proliferador de peroxisomas | |
DK0784054T3 (da) | 1,2,3,4-tetrahydroquinoxalinderivater og deres anvendelse som glutamatreceptorantagonister | |
DE3781080T2 (de) | 2-substituierte-e-kondensierte(1,2,4)triazolo-(1,5-c)pyrimidine, pharmazeutische zubereitungen und ihre verwendung. | |
AU2001235838A1 (en) | Imidazol derivatives as raf kinase inhibitors | |
NO20053302D0 (no) | Imidazolderivater med affinitet for alfa 2-reseptoraktivitet. | |
MY134226A (en) | 1,2-dihydropyrazol-3-ones which control inflammatory cyctokines | |
EP1151993A4 (en) | CYCLIC AMINE DERIVATIVES AND THEIR APPLICATIONS | |
ATE268769T1 (de) | Pyrimidinderivate mit antitumor-wirkung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |